MKSI · MKS Inc.

The thesis

MKS Inc. sells instruments, lasers and process-chemistry equipment to chipmakers and electronics-packaging makers. Its shares have fallen to $196.11 (adjusted daily close, 22 October 2026), and the third-quarter report after the market close on 4 November 2026 decides whether revenue clears the $1.310 billion floor of company guidance. The company confirmed that date on 12 October 2026, with a conference call at 8:30 a.m. Eastern on 5 November 2026.

The 14-day relative strength index (a 0–100 momentum gauge) reads 11.2, a level that marks an unusually one-sided decline. The narrative is saturated: coverage is heavy, target cuts followed the August report, and the shares kept falling after MKS announced the $650 million sale of its Ophir Optics unit on 19 October 2026.

Bullish and bearish views on MKS Inc.

The bull case on MKS Inc. (MKSI), in brief: Guidance is above where the shares trade. The bear case: Good results have not lifted the shares.

Bull case

• Guidance is above where the shares trade. On 5 August 2026 MKS guided third-quarter revenue to $1.350 billion, plus or minus $40 million, and adjusted EBITDA (earnings before interest, tax, depreciation and amortization) to $395 million, plus or minus $28 million. A report inside that range would show the operating case intact while the price has fallen.
• Second-quarter results were solid. MKS reported revenue of $1.248 billion and non-GAAP earnings per share of $3.30 on 5 August 2026. Semiconductor revenue was $554 million and Electronics & Packaging revenue was $381 million.
• The Ophir Optics sale brings in cash. MKS agreed on 19 October 2026 to sell Ophir Optics to TTM Technologies for $650 million in cash, which the company put at over 18 times projected 2026 adjusted EBITDA. CEO John T.C. Lee said it would help MKS "further strengthen our balance sheet."
• Debt reduction has started. MKS disclosed a voluntary $100 million term-loan prepayment in August 2026, and net leverage was 3.0 times at the second-quarter report.
• Analysts still carry targets far above the price. Morgan Stanley's target is $345 (Overweight, 17 September 2026) and Mizuho's is $330 (Outperform, 25 August 2026). Both sit well above the $196.11 close.

Bear case

• Good results have not lifted the shares. The shares fell after the 5 August 2026 report and have kept falling into the 4 November 2026 report, from $264.50 on 9 October 2026 to $196.11 on 22 October 2026. The market is paying a lower multiple for the same earnings.
• Targets have been cut. Morgan Stanley lowered its target to $345 from $439 on 17 September 2026, and Mizuho lowered its target to $330 from $360 on 25 August 2026. A news summary on 12 October 2026 linked the October weakness to a broad sell-off in chip-equipment shares, not to company news.
• Use of the Ophir proceeds is not stated. MKS's 19 October 2026 release does not say whether the cash goes to debt reduction, and it does not give Ophir Optics' revenue. Closing is targeted for the second quarter of 2027, subject to regulatory approvals, so no cash arrives before then.
• The balance sheet is a constraint. MKS had $1.4 billion of convertible senior notes and €1.0 billion of senior notes outstanding at 30 June 2026. The convertible notes were convertible at holders' option during the third quarter.
• The prior recovery level failed. The $255.76 weekly-close level used in the 10 October 2026 note sits well above the $196.11 close, so the recovery case that note described no longer holds.

Price setup

The adjusted daily close was $196.11 on 22 October 2026, against $264.50 on 9 October 2026. The shares are 55.9% below the 52-week high of $444.39. The 14-day relative strength index of 11.2 is the lowest reading in this dossier's coverage.

The $255.76 close of 28 August 2026 and the $264.50 close of 9 October 2026 are now overhead levels the shares would have to recover. No daily close in the coverage period since June sits below $196.11 in the figures reviewed, so there is no nearer support to cite than the invalidation level below.

Crowding evidence points to forced or heavy selling, not extended buying: a 37.8% three-month decline, a momentum reading of 11.2 and an earnings report 13 days away. No SEC Form 4 insider transactions were found in the sources checked.

Catalysts, next 30 days

• Second quarter of 2027, targeted: Ophir Optics sale closing. Closing depends on regulatory approvals and governmental consents.

Elapsed catalysts

• 4 November 2026 (after the US market close): MKS third-quarter 2026 results. The company announced this date on 12 October 2026. The report settles whether revenue reaches $1.310–1.390 billion and whether net leverage falls below 3.0 times. (passed 2d ago)
• 5 November 2026, 8:30 a.m. Eastern: earnings conference call. Management may say how it intends to use the Ophir Optics proceeds and how it sees fourth-quarter demand from chipmakers. (passed 1d ago)

What would change the view

Third-quarter revenue below the $1.310 billion guidance floor would break the case, because it would show the operating results no longer support the price. Net leverage at or above 3.0 times in the same report, with no stated plan for the Ophir proceeds, would also weaken it. A fourth-quarter outlook that cuts the chipmaker demand picture would extend the decline in the equipment multiple.

The price condition is a daily close below $175, a level under the 22 October 2026 close of $196.11 that would extend the current slide. A report inside the guidance range with falling leverage, followed by a recovery above the $255.76 close of 28 August 2026, would show the market re-rating the shares.

What it trades with

The shares have moved with chip-equipment and semiconductor stocks. A 12 October 2026 news summary tied the October weakness to sector weakness and not to company news. Applied Materials is another equipment maker whose analyst targets were in the news on 29 June 2026. Chipmaker capital spending plans and memory-chip demand are the outside drivers of MKS's semiconductor revenue.